Our vision is to have screening covering all cancers, available to everyone, everywhere.

About us: The Company

About us. Tumour Trace is dedicated to developing innovative, patented cancer screening and diagnostic technology. Based on peer review research our in- vitro portable screening device has been validated following proof of concepts in the UK, Serbia and India. Our vision is to enable screening covering all cancers to be available to everyone, everywhere.

Our Unique Process

Tumour Trace

Tumour Trace uses a patented Opto-Magnetic Imaging Spectroscopy (OMIS) methodology which delivers objective results faster, at less cost and more accurately than existing methodology. Using our technology, results can be available at the point of the test or in the laboratory.

Stained or Unstained Smears

Our methodology can use either stained or unstained samples. Results are based on image processing and a statistical learning algorithm that gives results within 10 minutes. Initial studies for cervical cancer have shown an average accuracy of 95% with a sensitivity of 95.2% and a specificity of 99% with unstained inner samples.

Fast and Objective Results

Using the Opto-Magnetic (OMIS) methodology, results are available much faster with a lower percentage of false negatives than existing cancer screening methodologies. The major benefits are faster diagnosis leading to earlier treatment, which in turn can reduce costs, increase survival rates and reduce patient anxiety.

Our Passion


Cases of cancer are continuing to grow and the cost of screening, diagnosis and treatment are forecast to increase substantially over the next 20 years.

Our goals are simple: to enable increased levels of screening, provide objective diagnosis faster and more accurately; and provide the technology so that everyone, wherever they are in the world, can be included in a screening programme.

We have been developing the Opto-Magnetic Imaging Spectroscopy (OMIS) methodology for several years and have undertaken a number of successful validation trials in the UK, Serbia and India. We are confident that our first model will receive the CE Mark for an in-vitro diagnostics medical device early in Q2 this year for cervical, prostate, colon and oral cancers.

Much of our initial work has centred on cervical cancer, which is the 4th largest cancer in the world. Current methodology for cervical cancer using Pap/LBC methodology delivers, at best, sensitivity and specificity at 56.75% and 97.75% respectively, compared with the Tumour Trace Opto-Magnetic Imaging Spectroscopy (OMIS) method which has achieved sensitivity and specificity of 95.24% and 99% respectively.

We have also carried out preliminary tests for prostate cancer.  Current test results are, at best, 63% accurate versus the OMIS methodology which has achieved 73% accuracy.  These results have had preliminary validation with a blind study at the John van Geest Cancer Research Centre in Nottingham.